Literature DB >> 28989112

A comparison of apremilast monotherapy and combination therapy for plaque psoriasis in clinical practice: A Canadian multicenter retrospective study.

Arvin Ighani1, Jorge R Georgakopoulos2, Scott Walsh3, Neil H Shear3, Jensen Yeung4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28989112     DOI： 10.1016/j.jaad.2017.09.060

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

1.  Combination Therapy with Apremilast and Biologics for Psoriasis: A Systematic Review.

Authors:  Mette Gyldenløve; Farzad Alinaghi; Claus Zachariae; Lone Skov; Alexander Egeberg
Journal:  Am J Clin Dermatol       Date:  2022-06-23       Impact factor: 6.233

2.  Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy.

Authors:  Marco Galluzzo; Simone D'Adamio; Elena Campione; Luca Bianchi; Marina Talamonti
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

3.  Real-world Efficacy and Safety of Apremilast Monotherapy in the Management of Moderate-to-severe Psoriasis.

Authors:  Bela J Shah; Deval Mistry; Navin Chaudhary; Shikha Shah
Journal:  Indian Dermatol Online J       Date:  2020-01-13

4.  Cost-utility and budget impact analysis of adding-on apremilast to biologic therapy in the treatment of moderate to severe plaque psoriasis, an Iranian payer perspective.

Authors:  Marzieh Zargaran; Fatemeh Soleymani; Saman Ahmad Nasrollahi; Meysam Seyedifar; Mohammad Mehdi Ashrafian Rahaghi
Journal:  Res Pharm Sci       Date:  2021-06-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.